🔴 NTHI is trading 5.5% down today as a $75 million share issuance outweighs UAE IND approval

NTHI is trading 5.5% down at $4.45 as a potential $75 million share issuance creates a financing overhang, overshadowing positive regulatory news.

• The company received a second UAE IND approval for NEO100, expanding its CNS cancer program, but the regulatory win is being ignored by investors.
• Sentiment is currently dominated by the potential dilution from the $75 million financing plan.
• The decline appears company-specific as the stock underperforms despite mixed broader market conditions.